Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 8, 2026. The filing details the reconvened 2026 Annual Meeting of Stockholders for Jaguar Health, Inc., which was previously adjourned on May 22, 2026, and June 2, 2026. The meeting was held to vote on five specific proposals submitted to the Company's stockholders.
Key Financial Metrics
This filing is a corporate governance report regarding stockholder votes and does not contain financial performance data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
As of the record date (April 15, 2026), there were 14,044,277 shares of Common Stock issued and outstanding. A total of 7,169,152 shares were represented at the meeting. All five proposals were approved by the stockholders:
- Proposal 1 (Director Election): Elected John Micek III as a Class II director for a three-year term. Votes: 3,967,085 For; 240,944 Withheld; 2,961,123 Broker Non-Votes.
- Proposal 2 (Auditor Ratification): Ratified the appointment of RBSM LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes: 6,898,326 For; 238,443 Against; 32,383 Abstained.
- Proposal 3 (ELOC Agreement): Approved the issuance of more than 19.99% of outstanding Common Stock to C/M Capital Master Fund, LP (and affiliates) pursuant to a securities purchase agreement (ELOC Agreement) to be entered into within 90 days. Votes: 3,891,273 For; 291,441 Against; 25,315 Abstained; 2,961,123 Broker Non-Votes.
- Proposal 4 (Preferred Stock Purchase): Approved the issuance of more than 19.99% of outstanding Common Stock to C/M Capital pursuant to a Preferred Stock Purchase Agreement. This includes shares of Common Stock issuable upon redemption of a new Series P Non-Convertible Preferred Stock. Votes: 3,846,847 For; 336,712 Against; 24,470 Abstained; 2,961,123 Broker Non-Votes.
- Proposal 5 (Adjournment Authority): Granted discretionary authority to adjourn the meeting to solicit additional proxies if necessary to approve Proposals 3 and 4. Votes: 3,928,027 For; 258,049 Against; 21,953 Abstained; 2,961,123 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance or management commentary on future operational outlook. The primary contingency noted is the execution of the ELOC Agreement and Preferred Stock Purchase Agreement with C/M Capital, which must be finalized within 90 days following the Annual Meeting. The significant number of Broker Non-Votes (2,961,123) on Proposals 1, 3, 4, and 5 indicates a substantial portion of shares held in street name did not receive voting instructions for those specific matters.
Key Facts for Investor Verification
- Verify the final terms and execution date of the ELOC Agreement and Preferred Stock Purchase Agreement with C/M Capital, as these involve significant equity issuance (>19.99% of outstanding shares).
- Confirm the impact of the new Series P Non-Convertible Preferred Stock on the Company's capital structure and potential dilution upon redemption.
- Review the definitive proxy statement (Schedule 14A) filed on April 30, 2026, for detailed descriptions of the proposals and the rationale behind the financing arrangements.
- Monitor the Company's cash position and liquidity needs, given the reliance on this equity financing to support operations.